Review Article
Effect of Inulin-Type Carbohydrates on Insulin Resistance in Patients with Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis
Table 1
The characteristics of the studies included in meta-analysis.
| | Study | Design | Sample size (ITC/Con) | Gender (M/W) | Age (years) ITC vs. Con | Baseline weight (kg) ITC vs. Con | Baseline BMI (kg/m2) ITC vs. Con | ITC dose (g/d) | Duration | ITC total dose (g) | Control | Diabetes duration (year) ITC vs. Con | Hypoglycemic agents |
| | Ghavami 2018 [24] | R, DB, P | 46 (23/23) | 10/13
10/13 |
|
| | 10 | 6 w | 420 | Starch powder |
| Glucose-lowering drugs | | Gargari 2013 [25] | R, TB, P | 49 (24/25) | 0/24
0/25 |
|
|
| 10 | 2 m | 600 | Maltodextrin |
| Metformin
Glibenclamide | | Dehghan 2013 [23] | R, P | 49 (24/25) | 0/24
0/25 |
|
|
| 10 | 8 w | 560 | Maltodextrin |
| Metformin
Glibenclamide | | Dehghan 2016 [24] | R, DB, P | 49 (27/22) | 0/27
0/22 |
|
|
| 10 | 2 m | 600 | Maltodextrin |
| NG | | Dehghan-1 2014 [25] | R, TB, P | 49 (24/25) | 0/24
0/25 |
|
|
| 10 | 8 w | 560 | Maltodextrin |
| Metformin
Glibenclamide | | Cai 2018 [26] | R, DB, P | 99 (49/50) | 16/33
22/28 |
|
|
| 7.5 | 12 w | 630 | Placebo milk powder |
(m) | Oral diabetic medication | | Dehghan-2 2014 [27] | R, TB, P | 52 (27/25) | 0/27
0/25 |
|
|
| 10 | 8 w | 560 | Maltodextrin |
| Metformin
Glibenclamide | | Farhangi 2016 [28] | R, DB, P | 49 (27/22) | 0/27
0/22 |
| NG |
| 10 | 2 m | 600 | Maltodextrin |
| Metformin
Glibenclamide | | Asemi 2016 [29] | R, DB, C | 51 (25/26) | 16/35 | |
|
| 2.7 | 6 w | 113.4 | Control food | NG | NG | | Tajadadi-Ebrahimi 2014 [30] | R, DB, P | 81 (27/27) | 5/22
5/22 |
|
|
| 8.4 | 8 w | 470.4 | Control bread | NG | Metformin
Glibenclamide | | Tajadadi-Ebrahimi 2017 [31] | R, DB, P | 60 (30/30) | NG |
|
|
| 0.8 | 12 w | 67.2 | Placebo | NG | NG |
|
|
Abbreviations: R: randomized; DB: double-blind; TB: triple-blind; C: crossover; P: parallel; ITC: inulin-type carbohydrate; Con: control; BMI: body mass index; w: weeks; m: months; NG: not given.
|
